Syntax Bio, a synthetic biology company programming the next generation of cell therapies, and Applied StemCell Corp. (ASC), ...
BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025 SEATTLE & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BrainChild Bio, Inc., a clinical ...
CHICAGO--(BUSINESS WIRE)--Syntax Bio, a synthetic biology company programming next generation cell therapies, today announced a research and development collaboration with Mayo Clinic focused on ...
Jonathan Kotula: We think there needs to be a systems-level approach to deal with complex diseases such as cancer. A lot of what has been done so far are reductionist approaches—one small molecule for ...
The collaboration will evaluate Ajinomoto Group’s stem cell culture products using Syntax Bio’s programmable stem cell ...
One of ANSTO's advanced imaging instruments Dingo now delivers a rare fusion of simulation and radiobiology, becoming a launchpad for an innovative neutron therapy innovation. This unique scientific ...
Recipharm Advanced Bio, a segment of CDMO Recipharm, and Infant Bacterial Therapeutics (IBT) began a process performance qualification (PPQ) for IBT’s lead product, IBP-9414. The PPQ program will take ...
Bio X Cell, the global leader of functional antibodies for in vivo and emerging preclinical models, unveils a refreshed brand identity which bridges nearly 30 years of scientific leadership in the ...
3D organoid models are enabling researchers to advance their understanding of disease biology through the flexibility of in vitro models that more closely reflect in vivo biology. 2D cell models have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results